Greenland Mines Ltd (GRML) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) underwent a strategic transformation in March 2026 via the acquisition of Greenland Mines Corp., shifting its focus to two reportable segments: Mining (exploration of the Skaergaard Project in Greenland) and Biotech (development of gene therapies for neurodegenerative diseases). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,542,263) | $(6,327,213) |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.21) |
| Cash and Cash Equivalents (Ending) | $9,344,357 | $8,430,946 |
| Net Cash Used in Operating Activities | $(11,825,021) | $(3,491,178) |
| Net Cash Provided by Financing Activities | $14,786,767 | $11,858,383 |
| Total Assets | $65,013,052 | $9,593,240 |
| Total Liabilities | $7,109,200 | $129,764 |
| Stockholders' Equity | $57,903,852 | $9,463,476 |
Material Changes vs. Prior Period
- Asset Acquisition: Total assets increased by approximately $55.4 million, primarily driven by the March 2026 acquisition of mineral exploration rights valued at $48.4 million. This was funded largely by the issuance of Series C Preferred Stock.
- Operating Expenses: Operating expenses surged to $15.0 million (vs. $3.5 million in the prior year), a 331% increase. This was driven by a $5.2 million increase in professional fees and a $5.2 million increase in general and administrative expenses (largely due to $4.2 million in share-based compensation).
- New Expense Categories: The company incurred $561,030 in exploration and evaluation expenses related to the Skaergaard Project, a new line item not present in the prior period.
- Impairment: A one-time impairment charge of $2.0 million was recognized for fully impaired biotech licenses (generic drugs) in Q1 2026.
- Derivative Liability: The fair value of warrant liabilities increased to $5.9 million from $53,000 at year-end 2025, resulting in a $499,120 expense for the six-month period.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding. The company relies on equity or debt financing to fund operations and the pending acquisition of Neo North Star Resources.
- Pending Acquisition: The company has agreed to acquire Neo North Star Resources for $35 million ($20 million cash, $15 million stock). The cash portion exceeds current cash on hand, necessitating new financing. A $1 million termination fee applies if the deal fails due to lack of Greenland government approval by September 1, 2026.
- Nasdaq Compliance: The company is not in compliance with the Nasdaq minimum bid price rule ($1.00). It has until September 14, 2026, to regain compliance. Stockholders have authorized a reverse stock split (up to 1-for-60) to address this, but no split has been effected as of the filing date.
- Capital Raising: The company terminated its At-the-Market (ATM) sales agreement effective July 4, 2026, removing a key liquidity source. Recent financing included a $7.75 million private placement in March and a $3.75 million private placement in June.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing inadequate accounting resources and lack of segregation of duties.
Investor Verification Checklist
- Financing for Neo North Star: Verify the company's ability to secure the $20 million cash required for the pending acquisition before the September 1, 2026 deadline.
- Nasdaq Delisting Risk: Monitor the stock price and the execution of the authorized reverse stock split to ensure compliance with Nasdaq listing rules by September 14, 2026.
- Series C Preferred Stock: Review the terms of the 47,940 Series C Preferred shares issued for the Greenland Mines acquisition, noting they are non-voting and non-convertible until stockholder approval is obtained.
- Exploration Progress: Assess the technical feasibility and economic viability of the Skaergaard Project, as the company currently holds no proven mineral reserves.
- Internal Control Remediation: Track progress on remediation of material weaknesses in internal controls to ensure future financial reporting reliability.